Publications by authors named "F Koinis"
The increased metastatic ability of small-cell lung cancer (SCLC) necessitates the identification of new prognostic biomarkers for clinical evaluation during the disease course. Our previous research highlighted the clinical relevance of transcription factor JunB (JUNB), C-X-C chemokine receptor type 4 (CXCR4), and programmed cell death 1 ligand 1 (PD-L1) in breast and non-small cell lung cancer (NSCLC) patients. In the current study, we examined these biomarkers in circulating tumor cells (CTCs) and plasma-derived exosomes from 100 treatment-naïve SCLC patients.
View Article and Find Full Text PDFCXCR4, JUNB and PD-L1 are implicated in cancer progression and metastasis. The current study investigated these biomarkers in CTCs isolated from metastatic prostate cancer (mPCa) patients at the RNA and protein levels. CTCs were isolated from 48 mPCa patients using the Ficoll density gradient and ISET system (17 out of 48).
View Article and Find Full Text PDFArticle Synopsis
- The study investigated the clinical significance of circulating tumor cells (CTCs) in patients with metastatic castration-resistant prostate cancer (mCRPC) who were receiving cabazitaxel treatment.
- Results showed that a high number of CTCs detected at baseline and after the first treatment cycle were linked to shorter progression-free survival (PFS) and overall survival (OS).
- The presence of non-apoptotic CTCs at baseline was identified as an independent predictor of poorer OS, suggesting that monitoring CTCs could help gauge treatment effectiveness and patient prognosis.
Article Synopsis
- The study aimed to assess the prevalence and significance of gene alterations in European prostate cancer patients using a specific genetic testing panel targeting 36 key genes.
- A total of 196 patients were analyzed, revealing that 61% had gene alterations, with 17.3% specifically showing changes in homologous recombination repair (HRR) genes.
- The presence of HRR gene alterations did not correlate with factors such as disease stage, age, or overall survival, highlighting the need for further research on their predictive value in treatment approaches.
Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype. There are few targeted therapies for these patients, leading to an unmet need for new biomarkers. The present study aimed to investigate the expression of PD-L1, CTLA-4, GLU, and VIM in CTCs of TNBC patients.
View Article and Find Full Text PDF